Triple therapy for lung disease from biomass smoke
Part of Infections, Lungs & breathing clinical trials.
This trial is testing a combination of three inhaled medicines (triple therapy) to see how well they help the small airways in people whose lung disease is caused by breathing in smoke from cooking or heating with wood or other biomass fuels. It may be a good fit if you have COPD or chronic bronchitis from this type of exposure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been exposed to wood or biomass smoke for more than 100 hours total (or more than 10 years of daily exposure).
- You have been diagnosed with COPD or chronic bronchitis.
- You are not pregnant or breastfeeding.
- You have not had a flare-up or lung infection in the last 4 weeks.
- You do not have other serious health issues (like cancer, uncontrolled diabetes, or heart problems) that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a third medicine (fluticasone furoate/vilanterol/umeclidinium) to a two-medicine inhaler (vilanterol/umeclidinium) can reduce air trapping and inflammation in the lungs and blood of people with COPD GOLD B. It may help you breathe better and have fewer symptoms.
This trial looks at whether using one or more inhalers, together with a smartphone app, can help people manage chronic obstructive pulmonary disease (COPD) better. You may be eligible if you have COPD, need “triple therapy” (three medicine types), and can use the app and surveys.
This trial tests a new inhaler that combines three medicines (fluticasone, formoterol, and glycopyrronium) to see if it helps people with chronic obstructive pulmonary disease (COPD) breathe better and have fewer flare-ups. It may be an option if you have COPD and are looking for a convenient once- or twice-daily treatment.
This study tests a combination inhaler medicine in people with early signs of lung function decline and a smoking history. The goal is to see if this three-drug combination can help improve breathing and prevent further lung damage.
This study uses a special MRI scan to see how well a single triple inhaler works for people with COPD who have moderate to severe shortness of breath or feel their health is not good. It compares two groups: those with a low risk of flare-ups and those with a high risk, to find out if the treatment helps both groups.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
Hear when a new COPD Bronchitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.